BPC-157 vs LL-37
A peptide sold to heal tendons, muscles and the gut. It has been tested mostly in rats, and the only human report covers 12 patients. It is sold as an injected natural antibiotic and healer. The only trials used it on skin sores and gave mixed results, and injecting it has never been studied in people.
Both sit at grade C: animal and cell studies. Neither is FDA approved.
Evidence
CAnimal and cell studies
CAnimal and cell studies
Human studies cited
Animal or cell studies cited
Why the grade
A 2025 systematic review found 36 studies of BPC-157 for musculoskeletal injury: 35 preclinical, almost all in rats from one Zagreb research group, and one retrospective human series of 12 patients with knee pain. No randomized or controlled human trial has been published, so the healing claims rest on animal data (grade C). A second review, searching to June 2026, found nothing new.
Two randomized placebo-controlled trials exist, both of LL-37 applied topically to chronic wounds: 148 patients with venous leg ulcers (negative on the primary endpoint) and a smaller diabetic foot ulcer trial. The injected 'immune support' use sold online has no human data at all. The rest of the human literature is observational work on the body's own LL-37 in wounds, psoriasis, and rosacea, plus cell and mouse mechanism studies. For the use it is sold for, that is C.
FDA
Not approved
BPC-157 is not approved by the FDA for any use and is sold as a research chemical. On 28 October 2026 HHS issued an enforcement discretion policy. Under it, HHS will not act against state-licensed pharmacies and physicians that compound BPC-157 acetate for a named patient, by injection, by mouth or on the skin, if they meet sourcing, testing, labeling and reporting conditions. The policy is not an approval and does not add BPC-157 to the 503A bulks list. It lasts until a final rule settles that question.
Not approved
Not approved by the FDA for any use and sold as a research chemical. LL-37 was nominated for the FDA's compounding bulk-substances list and placed in Category 2 (significant safety risk); the nomination was withdrawn, the FDA removed it from the category in April 2026, and a Pharmacy Compounding Advisory Committee review is planned before the end of February 2027.
Sold for
BPC-157 is sold as a healing peptide for tendons, ligaments, muscle and gut, taken by injection or orally, and is one of the most popular compounds in the grey-market peptide trade.
LL-37 is sold as an injectable 'natural antibiotic' that fights infections, breaks up biofilms, heals wounds, and modulates immunity.
Studies say
Dozens of rat studies, nearly all from one laboratory, show faster tendon, ligament and gut healing, but the only human data are a 12-patient uncontrolled series, so nothing is established in people (grade C).
Topical LL-37 has two small wound-healing trials with mixed results, the body's own LL-37 is well studied and drives inflammation in psoriasis and rosacea, and there are no human data on injecting it, so the evidence for the marketed use is grade C.
Class
Synthetic pentadecapeptide (gastric-derived)
Host-defense antimicrobial peptide
Route
Several routes
Injection